Healthcare / BiotechnologyNasdaqCM
$3.08
-0.07 (-2.22%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-4.3M · quality 37.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$13M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-38.8%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-159.8%
FCF / Net income
0.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.1M · net income $-3.5M · FCF $-3.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | $2.1M | $2.1M | $2.0M | — | $297000.00 | $3.9M | $2.3M | $4.5M | — |
| Net Income | $-3.5M | $-3.5M | $-3.1M | $-5.3M | $-44.1M | $-51.6M | $-77.8M | $-123.0M | $-115.3M |
| EBITDA | $-5.0M | $-5.0M | $-3.6M | $-9.6M | $-18.5M | $-54.7M | $-79.0M | $-122.3M | $-113.7M |
| EPS | — | — | -1.21 | -2.25 | -20.28 | -26.40 | — | — | — |
| Operating Margin | -239.8% | -239.8% | -181.4% | — | -6242.4% | -1400.2% | -3539.4% | -2774.3% | — |
| Net Margin | -170.1% | -170.1% | -152.8% | — | -14841.1% | -1310.2% | -3388.6% | -2729.3% | — |
| Balance Sheet | |||||||||
| Current Ratio | 1.80 | 1.80 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-3.3M | $-3.3M | $-4.3M | $-21.2M | $-40.6M | $-36.5M | $-74.0M | $-109.1M | $-100.9M |
| Returns | |||||||||
| ROE | -38.8% | -38.8% | -34.5% | -46.6% | -421.7% | -107.0% | -130.8% | -125.9% | 1103.4% |
| Valuation | |||||||||
| P/B | 1.30 | 1.30 | 0.92 | 0.76 | 2.63 | — | — | — | — |
| Growth & Yield | |||||||||
| Revenue Growth | 3.7% | 3.7% | — | — | — | 71.7% | -49.1% | — | — |
| EPS Growth | — | — | 46.2% | 88.9% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+9.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.21 → n/d
Residual
+9.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.